We have identified four particular areas of expertise, shown in the diagram below. As at 31 January 2014, the value of the top 30 investments in our portfolio stood at £226.1 million.
Biopharmaceutical company dedicated to identifying, validating, manufacturing and commercialising new cancer treatments
A medical device company whose leading product is a disposable tourniquet
A clinical-stage specialty biopharmaceutical company developing a range of novel immunotherapies